CECOG Academy

www.cecog.org

 

CECOG Academy
W

Immune CPIs in ES-SCLC: How Effective Are Durvalumab, Atezolizumab & Pembrolizumab?

By CECOG Academy FEATURING Wolfgang Kostler
By CECOG Academy FEATURING Wolfgang Kostler
111 views
March 24, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

21:24
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss
Videos
30:18

CPIs in Cancer Treatment: Key Components of the Immune Defence, Immu…

CECOG Academy

W. Berger

30:18

Rationale for Immune CPIs in Cancer Treatment: Key Concepts of the I…

CECOG Academy

W. Berger

20:56

Skeletal Health in Breast Cancer: Brief Comparison of BTAs in Advanc…

CECOG Academy

P. Dubsky

20 views
36:33

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

CECOG Academy

C. Zielinski

195 views
05:03

Immune CPIs in ES-SCLC: How Effective Are Durvalumab, Atezolizumab &…

CECOG Academy

W. Kostler

111 views
06:52

Immune CPIs in NSCLC: Durvalumab After cCRT for Stage III, 2L Nivo, …

CECOG Academy

W. Kostler

110 views
18:57

1L Immune CPIs Efficacy Review for Advanced NSCLC: Single Agent IO, …

CECOG Academy

W. Kostler

92 views
19:19

Skeletal Health in Lung Cancer: Prevalence of Bone Mets, Prevalence …

CECOG Academy

J. Spasic

116 views
28:04

Immune CPIs as Mono and Combination Therapy for RCC: New 1L Strategi…

CECOG Academy

M. Schmidinger

223 views
25:07

Skeletal Health in Prostate Cancer: What Is the Impact of Long-Term …

CECOG Academy

D. Santini

29 views